Market Overview

Q3 Earnings Outlook For Clorox

Share:

On Wednesday, May 1, Clorox (NYSE: CLX) will release its latest earnings report. Benzinga's outlook for Clorox is included in the following report.

Earnings and Revenue

Wall Street analysts see Clorox reporting earnings of $1.45 per share on revenue of $1.57 billion.

Clorox reported a profit of $1.37 when it published results during the same quarter last year. Sales in that period totaled $1.52 billion. The Wall Street consensus estimate for earnings would represent a 5.84 percent increase for the company. Sales would be have grown 3.49 percent from the same quarter last year. Here's how the company's reported EPS has stacked up against analyst estimates in the past:

 

Quarter Q2 2019 Q1 2019 Q4 2018 Q3 2018
EPS Estimate 1.31 1.58 1.57 1.31
EPS Actual 1.4 1.62 1.66 1.37

Stock Performance

For a full 12 months, the stock's return has risen by 32.18 percent. Given that these returns are generally positive, long-term shareholders are probably relaxed going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.

Analyst estimates have adjusted higher for EPS and revenues over the past 90 days. The most common rating from analysts on Clorox stock is a Sell. The strength of this rating has maintained conviction over the past three months.

Conference Call

Clorox is scheduled to hold a conference call at 1:30 p.m. ET and it can be accessed here: https://78449.choruscall.com/dataconf/productusers/clx/mediaframe/29681/indexr.html

Posted-In: Earnings News

 

Related Articles (CLX)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

CME Group Q1 Earnings Preview

G1 Therapeutics Hits Its Highest Level Of 2019: What You Need To Know